Related Experiment Video

Updated: Oct 3, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Angiogenesis inhibitors in the treatment of lung cancer

F A Shepherd1

  • 1Division of Medical Oncology, Department of Medicine, Princess Margaret Hospital, 610 University Avenue, 5-104, University of Toronto, Ont., Toronto, Canada, M5G 2M9. frances.shepard@uhn.on.ca

Lung Cancer (Amsterdam, Netherlands)
|December 13, 2001
PubMed

Insights

This study reviews emerging anti-angiogenesis therapies for lung cancer, including metalloproteinase inhibitors and tyrosine kinase inhibitors. Clinical trials are ongoing for various agents targeting tumor growth and vascularization in small cell and non-small cell lung cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis in lung cancer.
  • Several anti-angiogenesis strategies are under investigation to inhibit tumor progression.
  • Previous trials with interferon showed limited efficacy in small cell lung cancer (SCLC).

Purpose of the Study:

  • To review current and emerging anti-angiogenesis agents being studied in clinical trials for lung cancer.
  • To highlight specific inhibitors targeting metalloproteinases, vascular endothelial growth factor (VEGF), and tyrosine kinases.
  • To provide an overview of ongoing trials in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of ongoing and recently completed clinical trials for anti-angiogenesis agents in lung cancer.
  • Identification of key molecular targets, including matrix metalloproteinases (MMPs), VEGF, and receptor tyrosine kinases (TKs).
  • Summary of agents such as Marimastat, Prinomastat, BMS-275291, Neovastat, anti-VEGF antibodies, SU5416, SU6668, ZD4190, and Thalidomide.

Main Results:

  • Several metalloproteinase inhibitors (MMPIs) like Marimastat and Prinomastat have completed large randomized trials, with results pending.
  • Early trials of anti-VEGF agents in NSCLC showed modest improvements in response and survival, prompting larger studies.
  • Other agents targeting tyrosine kinases and VEGF receptors are in early-phase trials or preclinical development.

Conclusions:

  • A diverse range of anti-angiogenesis agents are in clinical development for lung cancer, targeting various pathways.
  • Ongoing trials are evaluating MMPIs, VEGF inhibitors, and tyrosine kinase inhibitors in both SCLC and NSCLC.
  • The efficacy and safety of these novel therapies will be determined by the results of ongoing and future clinical investigations.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...